{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:19:54Z","timestamp":1790741994460,"version":"4.1.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Monocyte-derived fibrocytes recently garnered attention because the novel pathogenesis of myelofibrosis (MF), and suppression of fibrocyte differentiation by serum amyloid P remarkably improved MF. We previously revealed that human fibrocytes highly expressed signaling lymphocytic activation molecule F7 (SLAMF7) compared with macrophages and that SLAMF7high monocytes in the peripheral blood (PB) of MF patients were significantly elevated relative to those in healthy controls (HCs). In this study, we evaluated SLAMF7high monocyte percentage in the PB of HCs, myeloproliferative neoplasm (MPN) patients with MF, and MPN patients without MF by using a cross-sectional approach. We found that MPN patients with MF who harbored JAK2V617F had a significantly elevated SLAMF7high monocyte percentage, which correlated positively with the JAK2V617F allele burden. In addition, the serum concentration of interleukin-1ra (IL-1ra) was significantly correlated with the SLAMF7high monocyte percentage and JAK2V617F allele burden. These findings suggest that both SLAMF7high monocytes and IL-1ra could be useful noninvasive markers of MF onset. Furthermore, the JAK2V617F allele burden of SLAMF7high monocytes was significantly higher than that of SLAMF7low monocytes and could be a potential target of elotuzumab (Elo), an anti-SLAMF7 antibody used for treating multiple myeloma. Elo independently inhibited differentiation of fibrocytes derived not only from HCs but also from MF patients in vitro. Elo also ameliorated MF and splenomegaly induced by romiplostim administration in humanized NOG mice. In conclusion, an increase of SLAMF7high monocytes with higher JAK2V617F allele burden was associated with the onset of MF in MPN patients harboring JAK2V617F, and Elo could be a therapeutic agent for MPN patients with MF who harbor JAK2V617F.<\/jats:p>","DOI":"10.1182\/blood.2019000051","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T22:25:20Z","timestamp":1562192720000},"page":"814-825","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab"],"prefix":"10.1182","volume":"134","author":[{"given":"Takaaki","family":"Maekawa","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikuni","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Takada","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Sone","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Ogata","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7067-1278","authenticated-orcid":false,"given":"Takuya","family":"Izumi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Nagao","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Takano","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Tachi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Hikota-Saga","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Endo-Umeda","sequence":"additional","affiliation":[{"name":"Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Uno","sequence":"additional","affiliation":[{"name":"Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Osawa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8733-1384","authenticated-orcid":false,"given":"Ken","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-3340","authenticated-orcid":false,"given":"Michihiro","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"International Research Center for Medical Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2531-4770","authenticated-orcid":false,"given":"Shinya","family":"Suzu","sequence":"additional","affiliation":[{"name":"Center for AIDS Research, Kumamoto University, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-4470","authenticated-orcid":false,"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soji","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Stem Cell Regulation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marito","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Stem Cell Regulation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-905X","authenticated-orcid":false,"given":"Makoto","family":"Makishima","sequence":"additional","affiliation":[{"name":"Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6223-9904","authenticated-orcid":false,"given":"Fumihiko","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, National Defense Medical College, Saitama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2020021109174563300_B1","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2020021109174563300_B2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.12772","article-title":"Thrombopoietin from beginning to end","volume":"165","author":"Hitchcock","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"2020021109174563300_B3","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1182\/blood.V87.11.4544.bloodjournal87114544","article-title":"Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice","volume":"87","author":"Ku","year":"1996","journal-title":"Blood"},{"issue":"11","key":"2020021109174563300_B4","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1182\/blood.V86.11.4025.bloodjournal86114025","article-title":"Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice","volume":"86","author":"Yan","year":"1995","journal-title":"Blood"},{"issue":"11","key":"2020021109174563300_B5","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood.V90.11.4369","article-title":"High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice","volume":"90","author":"Villeval","year":"1997","journal-title":"Blood"},{"issue":"7","key":"2020021109174563300_B6","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"5","key":"2020021109174563300_B7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2008-10-183558","article-title":"Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor","volume":"115","author":"Pecquet","year":"2010","journal-title":"Blood"},{"issue":"18","key":"2020021109174563300_B8","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","article-title":"Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim","volume":"114","author":"Kuter","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2020021109174563300_B9","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1038\/leu.2017.112","article-title":"Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis","volume":"31","author":"Maekawa","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2020021109174563300_B10","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.4049\/jimmunol.171.10.5537","article-title":"Inhibition of fibrocyte differentiation by serum amyloid P","volume":"171","author":"Pilling","year":"2003","journal-title":"J Immunol"},{"issue":"9","key":"2020021109174563300_B11","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J Exp Med"},{"issue":"1","key":"2020021109174563300_B12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF03403533","article-title":"Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair","volume":"1","author":"Bucala","year":"1994","journal-title":"Mol Med"},{"issue":"12","key":"2020021109174563300_B13","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.4049\/jimmunol.166.12.7556","article-title":"Peripheral blood fibrocytes: differentiation pathway and migration to wound sites","volume":"166","author":"Abe","year":"2001","journal-title":"J Immunol"},{"issue":"10","key":"2020021109174563300_B14","doi-asserted-by":"crossref","first-page":"e7475","DOI":"10.1371\/journal.pone.0007475","article-title":"Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts","volume":"4","author":"Pilling","year":"2009","journal-title":"PLoS One"},{"issue":"suppl 1","key":"2020021109174563300_B15","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/1755-1536-5-S1-S22","article-title":"Fibrocytes and the pathogenesis of diffuse parenchymal lung disease","volume":"5","author":"Mehrad","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"1","key":"2020021109174563300_B16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1755-1536-4-2","article-title":"The role of fibrocytes in fibrotic diseases of the lungs and heart","volume":"4","author":"Keeley","year":"2011","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"3","key":"2020021109174563300_B17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jhep.2006.04.014","article-title":"Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis","volume":"45","author":"Kisseleva","year":"2006","journal-title":"J Hepatol"},{"issue":"1","key":"2020021109174563300_B18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ki.2013.84","article-title":"Fibrocytes develop outside the kidney but contribute to renal fibrosis in a mouse model","volume":"84","author":"Reich","year":"2013","journal-title":"Kidney Int"},{"issue":"6","key":"2020021109174563300_B19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nri2990","article-title":"Fibrocytes: emerging effector cells in chronic inflammation","volume":"11","author":"Reilkoff","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2020021109174563300_B20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0014-4827(91)90478-D","article-title":"Hepatocyte cell lines established from transgenic mice harboring temperature-sensitive simian virus 40 large T-antigen gene","volume":"197","author":"Yanai","year":"1991","journal-title":"Exp Cell Res"},{"issue":"9","key":"2020021109174563300_B21","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.4049\/jimmunol.1500955","article-title":"Fibrocytes differ from macrophages but can be infected with HIV-1","volume":"195","author":"Hashimoto","year":"2015","journal-title":"J Immunol"},{"issue":"23","key":"2020021109174563300_B22","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"20","key":"2020021109174563300_B23","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2020021109174563300_B24","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"6","key":"2020021109174563300_B25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12185-018-2421-7","article-title":"Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms","volume":"107","author":"Misawa","year":"2018","journal-title":"Int J Hematol"},{"issue":"2","key":"2020021109174563300_B26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12185-014-1721-9","article-title":"Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia","volume":"101","author":"Shirane","year":"2015","journal-title":"Int J Hematol"},{"issue":"12","key":"2020021109174563300_B27","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.leukres.2011.06.016","article-title":"Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms","volume":"35","author":"Morishita","year":"2011","journal-title":"Leuk Res"},{"issue":"9","key":"2020021109174563300_B28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00277-008-0512-x","article-title":"Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases","volume":"87","author":"Rapado","year":"2008","journal-title":"Ann Hematol"},{"issue":"1-2","key":"2020021109174563300_B29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jim.2009.09.011","article-title":"Improved serum-free culture conditions for the differentiation of human and murine fibrocytes","volume":"351","author":"Pilling","year":"2009","journal-title":"J Immunol Methods"},{"issue":"3","key":"2020021109174563300_B30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10928-016-9469-x","article-title":"Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Gibiansky","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"15","key":"2020021109174563300_B31","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020021109174563300_B32","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bcp.12528","article-title":"A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-\u03b1 variant with peginterferon-\u03b1-2a in healthy subjects","volume":"79","author":"Zheng","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"2020021109174563300_B33","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","article-title":"NOD\/SCID\/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells","volume":"100","author":"Ito","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2020021109174563300_B34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2006-04-017681","article-title":"Hematopoietic stem cell-engrafted NOD\/SCID\/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses","volume":"109","author":"Watanabe","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2020021109174563300_B35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jim.2010.09.025","article-title":"Improved serum-free culture conditions for spleen-derived murine fibrocytes","volume":"363","author":"Crawford","year":"2010","journal-title":"J Immunol Methods"},{"issue":"1","key":"2020021109174563300_B36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12974-017-1023-2","article-title":"Distinct cytokine patterns may regulate the severity of neonatal asphyxia-an observational study","volume":"14","author":"Bajnok","year":"2017","journal-title":"J Neuroinflammation"},{"issue":"6","key":"2020021109174563300_B37","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2020021109174563300_B38","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3109\/10428194.2013.805329","article-title":"Anti-transforming growth factor-\u03b2 therapy in patients with myelofibrosis","volume":"55","author":"Mascarenhas","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020021109174563300_B39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.2001.02883.x","article-title":"A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia","volume":"114","author":"Mesa","year":"2001","journal-title":"Br J Haematol"},{"issue":"4","key":"2020021109174563300_B40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1189\/jlb.0112033","article-title":"Fc\u03b3RI mediates serum amyloid P inhibition of fibrocyte differentiation","volume":"92","author":"Crawford","year":"2012","journal-title":"J Leukoc Biol"},{"issue":"5","key":"2020021109174563300_B41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1358\/dnp.2010.23.5.1444206","article-title":"PRM-151 (recombinant human serum amyloid P\/pentraxin 2) for the treatment of fibrosis","volume":"23","author":"Duffield","year":"2010","journal-title":"Drug News Perspect"},{"issue":"1","key":"2020021109174563300_B42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","article-title":"SLAM family receptors and SAP adaptors in immunity","volume":"29","author":"Cannons","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"2020021109174563300_B43","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2020021109174563300_B44","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2020021109174563300_B45","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","article-title":"CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma","volume":"88","author":"Veillette","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"2020021109174563300_B46","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"2020021109174563300_B47","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020021109174563300_B48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev.immunol.16.1.27","article-title":"Interleukin-1 receptor antagonist: role in biology","volume":"16","author":"Arend","year":"1998","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2020021109174563300_B49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/1043-4666(93)90024-Y","article-title":"Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica","volume":"5","author":"Piguet","year":"1993","journal-title":"Cytokine"},{"key":"2020021109174563300_B50","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3389\/fimmu.2018.01611","article-title":"IL-1-IL-17 signaling axis contributes to fibrosis and inflammation in two different murine models of systemic sclerosis","volume":"9","author":"Park","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2020021109174563300_B51","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.1038\/ncomms10791","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis","volume":"7","author":"Iannitti","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"2020021109174563300_B52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2020021109174563300_B53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/10\/814\/1554464\/bloodbld2019000051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/10\/814\/1554464\/bloodbld2019000051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:51:03Z","timestamp":1581414663000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/10\/814\/260635\/Increased-SLAMF7high-monocytes-in-myelofibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,9,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000051","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]}}}